Abdominal pain frequency or change in frequency · adults and children with cystic fibrosis
It is very uncertain whether summary of findings: ECM changes frequency of bowel symptoms: abdominal pain (% of days affected) compared with ECT (very low certainty).
1 finding from 1 review
CFA: change in FFE (g/day) · adults and children with cystic fibrosis
Summary of findings: ECM showed no clear difference in CFA: change in FFE (g/day) compared with ECT (low certainty).
1 finding from 1 review
CFA: change in FFE (g/day) · children with cystic fibrosis and proven pancreatic insufficiency
It is very uncertain whether summary of findings: ECM changes CFA: change in FFE (g/day) compared with ECMM (very low certainty).
1 finding from 1 review
Abdominal pain frequency or change in frequency · adults and children with cystic fibrosis
Summary of findings: ECM (Creon®) showed no clear difference in frequency of bowel symptoms: proportion of days with abdominal pain compared with a different ECM (low certainty).
1 finding from 1 review
CFA: change in FFE (g/day) · children with cystic fibrosis
It is very uncertain whether summary of findings: ECM changes CFA: change in FFE (g/day) compared with TPE (very low certainty).
1 finding from 1 review
Abdominal pain frequency or change in frequency · adults with cystic fibrosis
It is very uncertain whether summary of findings: ECM changes frequency in bowel symptoms: abdominal pain (% of days affected) compared with NECT plus cimetidine (very low certainty).
1 finding from 1 review
CFA: FFE (g/day) · adults and children with cystic fibrosis
1 finding from 1 review
CFA: change in FFE (g/day) · adults with cystic fibrosis
Summary of findings: ECM showed no clear difference in CFA: change in FFE (g/day) compared with NECT plus cimetidine (low certainty).
1 finding from 1 review
Days missed from work or school · patients with sore throat
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Intervention not reported
Treatment failure day‐28 PCR‐adjusted(PP population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failure day‐28 PCR‐adjusted(PP population) (low certainty).
1 finding from 1 review
Intervention not reported
Treatment failureday‐28 PCR‐adjusted(ITT population) · children aged 14 years or younger with uncomplicated P falciparum malaria
The intervention showed no clear difference in treatment failureday‐28 PCR‐adjusted(ITT population) (low certainty).
1 finding from 1 review
All‐cause short‐term mortality: range 15 to 31 days · people with cardiogenic shock or low cardiac output syndrome
Levosimendan showed no clear difference in all‐cause short‐term mortality: range 15 to 31 days compared with dobutamine (low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause long‐term mortality: 60 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause long‐term mortality: 60 days compared with norepinephrine (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 30 days · adults with cardiogenic shock
It is very uncertain whether levosimendan changes all‐cause short‐term mortality: 30 days compared with enoximone (very low certainty).
1 finding from 1 review
All‐cause short‐term mortality: 28 days · adults with cardiogenic shock
It is very uncertain whether epinephrine changes all‐cause short‐term mortality: 28 days compared with norepinephrine‐dobutamine (very low certainty).
1 finding from 1 review
DVT (symptomatic, asymptomatic, non‐fatal) · people undergoing major amputation of the lower extremity
It is very uncertain whether unfractionated heparin changes DVT (symptomatic, asymptomatic, non‐fatal) (5 to 8 days after surgery) compared with low molecular weight heparin (very low certainty).
1 finding from 1 review